Growing in India remains priority, await direction from SC on Fortis plea: IHH Healthcare
IHH Healthcare had acquired a 31 percent controlling stake in Fortis in 2018, which triggered a mandatory open offer to acquire another 26 percent of Fortis' shares from the market.
New Delhi: Malaysian firm IHH Healthcare on Monday reiterated its intent to continue on its growth plans for Fortis Healthcare, and said growth in India remains a priority for the company.
The group had acquired a 31 percent controlling stake in Fortis in 2018, which triggered a mandatory open offer to acquire another 26 percent of Fortis' shares from the market.
Also Read: PIL to halt sewage treatment plant construction: Delhi HC seeks AIIMS reply
The open offer has not proceeded due to ongoing legal proceedings with respect to the transaction pending before the Supreme Court where the next hearing is scheduled for February 10, 2021, IHH Healthcare said in a statement.
"Growing in India remains a priority for IHH as it is one of our four home markets, together with Malaysia, Singapore and Turkey," IHH Healthcare MD and CEO Kelvin Loh said.
He added that the company respects and has full faith in the judicial process in India and looks forward to a favourable outcome so the firm can proceed with the open offer. "This will allow IHH to further invest into Fortis to provide even more support to the Indian healthcare sector, especially in critical times like now with COVID-19."
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.